Literature DB >> 19381054

[Inter-departmental differences in the eradication therapy for Helicobacter pylori infection: a single center study].

Woo Chul Chung1, Kang Moon Lee, Chang Nyol Paik, Jeong Rok Lee, Sung Hoon Jung, Jin Dong Kim, Sok Won Han, In Sik Chung.   

Abstract

BACKGROUND/AIMS: Eradication rates of Helicobacter pylori (H. pylori) tend to decrease over the last few years. Apart from the antibiotic resistance and patients compliance, various factors have an influence on the efficacy of eradication therapy. We analyzed the inter-departmental differences in the eradication therapy for H. pylori infection.
METHODS: Between January 2003 and June 2007, total 3,072 eradication regimens were prescribed to patients. Eradication rates according to departments - gastroenterology (GE), general internal medicine (IM) and family medicine (FM) - were analyzed retrospectively.
RESULTS: The overall eradication rate of first-line triple therapy was 82.5% and second-line quadruple therapy was 71.2%. In the department of IM and FM, the eradication therapy was applied more frequently to the patients with erosion only, not ulcer. Overall eradication rates according to the departments were 87.0% in GE, 81.1% in IM and 77.2% in FM (p=0.02 GE vs. IM and p<0.01 GE vs. FM, respectively). Eradication rate in patients with peptic ulcer was also significantly higher in GE compared with IM or FM.
CONCLUSIONS: In primary clinic (IM and FM), the eradication therapy was frequently applied to erosion. The eradication rates of H. pylori in GE department were significantly higher than those of IM or FM. Inter-departmental differences of the eradication rate might be caused by patients' compliance to prescribed medication.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19381054

Source DB:  PubMed          Journal:  Korean J Gastroenterol        ISSN: 1598-9992


  4 in total

1.  Rifaximin Plus Levofloxacin-Based Rescue Regimen for the Eradication of Helicobacter pylori.

Authors:  Sang-Pil Yun; Han Gyung Seon; Chang Soo Ok; Kwang Ho Yoo; Min Kyung Kang; Won Hee Kim; Chang Il Kwon; Kwang Hyun Ko; Seong Gyu Hwang; Pil Won Park; Sung Pyo Hong
Journal:  Gut Liver       Date:  2012-10-18       Impact factor: 4.519

2.  Long-term follow up Helicobacter Pylori reinfection rate after second-line treatment: bismuth-containing quadruple therapy versus moxifloxacin-based triple therapy.

Authors:  Min Soo Kim; Nayoung Kim; Sung Eun Kim; Hyun Jin Jo; Cheol Min Shin; Young Soo Park; Dong Ho Lee
Journal:  BMC Gastroenterol       Date:  2013-09-19       Impact factor: 3.067

3.  Meta-analysis of first-line triple therapy for helicobacter pylori eradication in Korea: is it time to change?

Authors:  Eun Jeong Gong; Sung-Cheol Yun; Hwoon-Yong Jung; Hyun Lim; Kwi-Sook Choi; Ji Yong Ahn; Jeong Hoon Lee; Do Hoon Kim; Kee Don Choi; Ho June Song; Gin Hyug Lee; Jin-Ho Kim
Journal:  J Korean Med Sci       Date:  2014-04-25       Impact factor: 2.153

4.  Clarithromycin-based standard triple therapy can still be effective for Helicobacter pylori eradication in some parts of the Korea.

Authors:  Kyu-Hyun Yoon; Sung Woon Park; Sang Wook Lee; Beom Jin Kim; Jae Gyu Kim
Journal:  J Korean Med Sci       Date:  2014-09-02       Impact factor: 2.153

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.